CFHR5抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CFHR5 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CFHR5 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CFHR5 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using CFHR5 mouse mAb with DAB staining.    

  
  

The CFHR5 antibody is associated with the study of Complement Factor H-Related Protein 5 (CFHR5), a member of the complement factor H (CFH) protein family involved in regulating the alternative pathway of the complement system. CFHR5 shares structural homology with CFH, containing conserved short consensus repeat (SCR) domains, but lacks the critical regulatory regions of CFH. It is thought to modulate complement activity by competing with CFH for binding to C3b or cell surfaces, potentially influencing inflammatory and immune responses.

Interest in CFHR5 antibodies arose from its link to kidney diseases. Mutations in the *CFHR5* gene are implicated in CFHR5 nephropathy, a rare inherited form of glomerulonephritis prevalent in Cypriot populations. Autoantibodies targeting CFHR5 have also been identified in autoimmune conditions like atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), where dysregulated complement activation damages tissues.

Research-grade CFHR5 antibodies are essential tools for detecting CFHR5 expression in tissues, studying its interaction with complement components, and elucidating its role in disease mechanisms. These antibodies aid in diagnosing complement-mediated disorders and developing targeted therapies, such as monoclonal antibodies or complement inhibitors, to restore regulatory balance. Ongoing studies aim to clarify CFHR5's precise functional role and its potential as a biomarker or therapeutic target in complement-driven pathologies.